# Diabetes Research Hub — Daily Iteration Report

**Date:** 2026-08-12 (Wednesday)
**Agent:** diabetes-research-iterate (autonomous scheduled run)

## Work Queue Items Processed (5)

### 1. vet_papers_batch — 13 papers re-vetted (no drift)
Re-checked the 13 oldest `last_checked` VETTED papers (all stamped 2026-04-21):
`25940230, 26106223, 26322160, 26378978, 26404926, 26590418, 26656660, 26784127`
and the 41.9M combination-therapy batch `41967038, 41958082, 41923724, 41923440, 41906653`.

- Metadata (title/journal/year) unchanged and internally consistent for all 13.
- **PMID 26404926** ("Staging Presymptomatic Type 1 Diabetes," Diabetes Care 2015;38(10):1964-74) independently **re-confirmed via web** — exact match (JDRF/Endocrine Society/ADA three-stage statement).
- **PMID 41967038** (Vit D + catechin / TGF-β1/SMAD diabetic cardiomyopathy, J Pharm Pharmacol Apr 2026): mechanism biologically consistent, PMID below the 42M fabrication threshold and API-verified 2026-04-21, **but the specific 2026 article did not surface in web search today**. Retained VETTED with a `pmid_reverify_pending` watch flag. **Not** asserting fabrication.
- `last_checked` advanced to 2026-08-12. Next oldest cohort = 2026-04-22 papers, queued for ~2026-08-19.

### 2. audit_gap #3 (GOLD — Insulin Resistance in Islet Transplant)
Fresh sweep on insulin-resistance-as-primary-endpoint islet transplant studies surfaced only insulin-**independence**/glycemic-control primary endpoints (Edmonton Protocol NEJMoa061267; 10-yr IAK cohort Diabetes Care 2019; 5-yr parallel cohort Transpl Int 2023, PMC10783428). No completed/registered study uses insulin-**resistance** as a primary islet-graft outcome. **REMAINS GOLD.** Next audit ~2026-09-11.

### 3. audit_gap #6 (GOLD — CAR-T Access Barriers → diabetes cell-therapy translation)
AJMC 2026 reaffirms active CAR-T access barriers (referral pathways, manufacturing timelines, reimbursement, site-of-care, geographic disparities). CAR-Treg for autoimmune diabetes remains **preclinical** (HLA-A2 CAR-Treg mouse islet models, Sci Transl Med adp6519; review PMC12661798); cost/manufacturing/autologous-source barriers explicitly flagged. New adjacent review Front Immunol 2026 (10.3389/fimmu.2026.1737202) discusses access/cost but is not a diabetes access-equity study. **REMAINS GOLD.** Next audit ~2026-09-11.

### 4. validate_path — rituximab → beta_cell (REAFFIRMED PARTIALLY_VALIDATED)
No new completed 2026 rituximab RCT/MA. Core evidence unchanged: Pescovitz NEJM 2009 (PMID 19940299) partial 12-mo C-peptide preservation; 2-yr wane (PMID 24026563); 2025 network MA (PMC12211534, 60 RCTs) still excludes anti-CD20/rituximab from the 11 interventions beating placebo at 12 months. **New watch item:** an ongoing Phase 2 rituximab-pvvr ± **sequential** abatacept trial (RTX wk1–4, abatacept from wk16 ×20 mo) aiming to enhance durability — no results yet. No upgrade.

### 5. Credibility sweep + full pipeline rebuild
- **Credibility sweep clean:** no PMIDs > 42,000,000 in any script; no "zero SAEs"/"zero rejection"/"curative"/"achieves-a-cure" overstatement (all "cure" hits are legitimate category labels or hedged phrasing).
- **Pipeline rebuild:** `run_quality_improvements.py` → **all 41 improvements [OK].**

## State
- Papers: 287 total (274 VETTED, 13 FLAGGED).
- Gaps: 15 (Gaps #3, #6 audit dates advanced to 2026-08-12).
- `run_history` entry #119 appended; state backed up to `agent_state.json.bak_2026-08-12`.

## Git Status
Commit/push remains **BLOCKED in sandbox** (OneDrive-protected `.git` lock regeneration + no GitHub auth) — see queue item #0. **All changes this run are saved to working files on disk regardless of git.** User must, from local PowerShell at `C:\Users\justi\OneDrive\Diabetes_Research`: `Remove-Item .git\*.lock; git add -A; git commit -m 'Daily iteration 2026-08-12'; git push`.
